BioMarin Pharmaceutical BMRN NASDAQ · Healthcare · United States
$56.70 -2.79% -$1.63
Summary
46 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 34% a year over the last 3 years.
- Out of every 100 USD of revenue, 15 USD is left as free cash.
- Analysts expect revenue to grow by 20% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 7.8 years of operating profit.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 20%. Earnings per share grew by 34% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $19.1M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 29
- Hold 12
- Sell 0
Today's price within the analysts' price targets
The average target of $90.53 is 60% above today's price. 71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 98%
- Royalty And Other 1.7%
By region
- UNITED STATES 49%
- Europe 28%
- Rest Of World 12%
- Latin America 11%
Product brings in 98% of revenue.
Segments in detail